These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36853791)

  • 1. ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis.
    Asaka S; Liu Y; Yu ZC; Rahmanto YS; Ono M; Asaka R; Miyamoto T; Yen TT; Ayhan A; Wang TL; Shih IM
    Mod Pathol; 2023 Feb; 36(2):100045. PubMed ID: 36853791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
    Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
    Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
    Chapel DB; Patil SA; Plagov A; Puranik R; Mendybaeva A; Steinhardt G; Wanjari P; Lastra RR; Kadri S; Segal JP; Ritterhouse LL
    Mod Pathol; 2019 Oct; 32(10):1508-1520. PubMed ID: 31186530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming.
    Suryo Rahmanto Y; Shen W; Shi X; Chen X; Yu Y; Yu ZC; Miyamoto T; Lee MH; Singh V; Asaka R; Shimberg G; Vitolo MI; Martin SS; Wirtz D; Drapkin R; Xuan J; Wang TL; Shih IM
    Nat Commun; 2020 Jun; 11(1):2717. PubMed ID: 32483112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.
    Russo M; Newell JM; Budurlean L; Houser KR; Sheldon K; Kesterson J; Phaeton R; Hossler C; Rosenberg J; DeGraff D; Shuman L; Broach JR; Warrick JI
    Cancer; 2020 Jun; 126(12):2775-2783. PubMed ID: 32187665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications.
    Orlandi A; Ferlosio A; Ciucci A; Francesconi A; Lifschitz-Mercer B; Gabbiani G; Spagnoli LG; Czernobilsky B
    Mod Pathol; 2006 Jun; 19(6):797-803. PubMed ID: 16575402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
    Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
    Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma.
    Mao TL; Ardighieri L; Ayhan A; Kuo KT; Wu CH; Wang TL; Shih IeM
    Am J Surg Pathol; 2013 Sep; 37(9):1342-8. PubMed ID: 24076775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.
    Coatham M; Li X; Karnezis AN; Hoang LN; Tessier-Cloutier B; Meng B; Soslow RA; Blake Gilks C; Huntsman DG; Stewart CJ; Postovit LM; Köbel M; Lee CH
    Mod Pathol; 2016 Dec; 29(12):1586-1593. PubMed ID: 27562491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma.
    Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI
    Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARID1 and BRG1 Expression in Endometrial Cancer.
    Kontomanolis EN; Symeonidis P; Nikolettos K; Perros P; Rody A; Tsikouras P; Nikolettos N; Giatromanolaki A
    In Vivo; 2024; 38(3):1260-1265. PubMed ID: 38688602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors.
    Ayhan A; Mao TL; Suryo Rahmanto Y; Zeppernick F; Ogawa H; Wu RC; Wang TL; Shih IeM
    J Pathol Clin Res; 2015 Jul; 1(3):186-93. PubMed ID: 27499903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
    J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
    Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
    Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
    Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
    Yen TT; Miyamoto T; Asaka S; Chui MH; Wang Y; Lin SF; Stone RL; Fader AN; Asaka R; Kashima H; Shiozawa T; Wang TL; Shih IM; Tanner EJ
    Gynecol Oncol; 2018 Sep; 150(3):426-431. PubMed ID: 30126589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
    Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
    PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SWI/SNF Antagonism of PRC2 Mediates Estrogen-Induced Progesterone Receptor Expression.
    Wilson MR; Reske JJ; Koeman J; Adams M; Joshi NR; Fazleabas AT; Chandler RL
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.